|
UNIDO
PROGRAMME TO SUPPORT MEDICAL DISPOSABLES CULSTER IN GUJARAT
United Nations Industrial Development
Organization (UNIDO) has identified Gujarat as an important cluster
location for Pharmaceuticals and Medical Devices Industry. A number
of support activities will be carried out by UNIDO for the
development of these industries particularly the Medical Devices
Industry in Gujarat.
As part of these progammes,
a Seminar on "Quality Scenario and New Challenges to Medical
Devices Industry of Gujarat" was jointly organised by Medical
Disposable Manufacturers’ Association and UNIDO on April 20, 2000.
It was also supported by BV Patel PERD Center, Ahmedabad.
The Seminar was inaugurated
by Mr SP Adesara, Commissioner, Food & Drug Control
Administration, Gujarat State, Mr RJ Shah, Chief Industrial Advisor,
Government of Gujarat, gave special address.
It is remarkable to
note that the small and medium scale medical products manufacturing
units contribute approximately 60% of country’s requirements.
Since the industry originated from small scale plastic medical
products manufacturers about 25 years back, it lacked in
infrastructure necessary for medical devices. However, with proper
nursing and support from the Food & Drug Control Commissionerate’s
office, particularly by technocrat Commissioner like Mr SP Adesara,
many of the manufacturers have been able to update their facilities
to meet national and international quality requirements. Mr SP
Adesara emphasised need for more and more quality consciousness
since the medical devices are as critical as pharmaceutical products
and could endanger the life of patients.
The seminar was a great success and
concluded by including the "Medical Devices Industry in the
Diagnostic Study of the Industry" being undertaken jointly by
UNIDO, Govt. of Gujarat, BV Patel PERD Center, etc. The suggestion
was given by Mr RJ Shah, Chief Industrial Advisor, Govt. of Gujarat
and was welcome by all the participating agencies and about 100
participants from more than 55 industrial units.
The objective of the diagnostic study is to
locate the origin, to identify the value chain, access the current
performance indices, the strengths, weaknesses, opportunities and
threats of the industry, the possible mechanisms of jointly
addressing such issues of common interest.
Back
|
|
CASIL
HEALTH PLANS TIE-UP WITH ANTEC
Casil Health Products Ltd, a group company of
Cadila Pharmaceuticals Ltd, is planning to sign an exclusive marketing
agreement with UK based Antec International in April 2000, according
to the company’s President B Ramanna.
Speaking to newspersons Mr
Ramanna said the proposed agreement would give his company exclusive
marketing rights in India for Antec’s world wide patented product
virkon. Virkon, which is a medical disinfectant, is currently marketed
and used in 19 countries across the world.
Comparing the efficacy of
Virkon with conventional disinfectants, Casil’s General Manager
(Sales & Mktg.) JS Lastado said all currently used disinfectants
had been available for decades and none was designed for infection
control. As against this, Virkon was developed a few years back and
was the only patented product available worldwide which was not a
single chemical agent.
(Ref: TOI dt. 30/3/2000)
Back
|
|
PHARMA
PACKAGING MARKET WORLDWIDE TO RISE MODESTLY
World demand for secondary and specialty
pharmaceutical packaging will increase just over three percent
annually to $5.3 billion in 2003. Strengthening of consumer protection
standards and the expanding use of packaging to differentiate multiple
source drugs, child resistant caps and dispensing closures will see
the fastest sales gains.
Global demand for secondary
pharmaceutical containers will expand to $2.5 billion in 2003.
The global market for pharmaceutical caps and
closures will expand 3.5 percent annually from 1998 to 2003. Rising
concerns about consumer safety will create above average growth
opportunities for child-resistant and tamper-evident caps in most
developed and more prosperous developing countries.
Pharmaceutical packaging
accessories will generate steady worldwide sales growth as government
regulations and industry standards impose more extensive labelling,
consumer information and tamper-evident requirements on drug markets.
(Ref: EPP dt. 17/2/2000)
Back
| Next
|
|
|
